The COVID-19 Vaccination Debate: COVID-19 and Celiac Disease

Hugh J. Freeman^1,

¹Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada

Cite this paper:
Hugh J. Freeman. The COVID-19 Vaccination Debate: COVID-19 and Celiac Disease. International Journal of Celiac Disease. 2021; 9(1):3-5. doi: 10.12691/ijcd-9-1-7

Abstract

COVID-19 is a novel coronavirus that appears to cause a systemic disorder largely marked by fever and respiratory symptoms as well as diarrhea. The agent gains access to respiratory and gastrointestinal cells through a complex molecular mechanism associated with increased ACE2 receptor expression on brush border membranes of epithelial cells. Because some autoimmune-based disorders, including celiac disease, appear to be at increased risk for viral and community-acquired bacterial infections, a number of preliminary survey studies from different countries, largely web-based or telephone-based, have suggested that COVID-19 infection risk is not increased in celiac disease. However, specific sub-groups of patients with celiac disease have not been thoroughly evaluated. For example, selective immunoglobulin A deficiency or other immune deficiency states with celiac disease may represent a special risk group for COVID-19 and other viral infectious agents.

Keywords:
COVID-19 SARS-COV-2 celiac disease Immune checkpoint receptors COVID-19 diarrhea

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
[2]	World Health Organization. Coronavirus disease (COVID-19) outbreak (http://www.who.int).
[3]	Zhuong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February 2003. Lancet 2003; 363: 1353-1358.
[4]	Ksiazek TG, Erdman D, Goldsmith CD, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953-1966.
[5]	Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967-1976.
[6]	Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814-1820.
[7]	Meng X, Lou Q-y, Yang W-y, et al. Gordian knot: gastrointestinal lesions caused by three pathogenic coronaviruses from SARS-CoV and MERS-CoV to SARS-CoV-2. Europ J Pharmacol 2021; 890: 173659.
[8]	Freeman HJ. COVID-19 diarrhea. Int J Celiac Disease 2020; 8: 60-63.
[9]	Lerner A. Covid-19 and the human gut: a new runner on the tract. Int J Celiac Disease 2020; 8: 64-67
[10]	Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382: 929-936.
[11]	Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158:1831-1833.
[12]	Zhou P, Yang L, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270-273.
[13]	Harmer D, Gilbert M , Borman R, et al. Quantitative mRNA expression profiling of ACE2, a novel homologue of angiotensin covering enzyme. FEBS Lett 2002; 532: 107-110.
[14]	Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-Cov-2 by full length human ACE2. Science 2020; 367: 1444-1448.
[15]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; In press.
[16]	Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology 2020; 158: 1518-1519.
[17]	Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012; 487: 477-481.
[18]	Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? J Crohn’s and Colitis 2020; 14: 1334-1336.
[19]	Meghool F, Valiani A, Safari T, et al. Gastrointestinal and renal complications in SARS-CoV-2 infected patients: role of immune system. Scans J Immunol 2020; 00: e12999.
[20]	Burgueno JF, Reich A, Hazime H, et al. Expression of SARS-CoV-2 entry molecules ACE2 and TMRSS2 in the gut of patients with IBD. Inflammatory Bowel Dis 2020; 26: 797-808.
[21]	Neurath MF. COVID-19 and immunomodulation in IBD. Gut 2020: 69: 1335-1342.
[22]	Emmi G, Bettiol A, Mattioni I, et al. SARS-CoV-2 infection among patients with systemic autoimmune disease. Autoimmunity Rev 2020; 19: 102575.
[23]	Marild K, Fredlund H, Ludvigsson JF. Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. Am J Gastroenterol 2010; 105: 2465-2473.
[24]	Zingone F, Abdul Sultan A, Crooks CJ, et al. The risk of community-acquired pneumonia among 9803 patients with celiac disease compared to the general population: a cohort study. Aliment Pharmacol There 2016; 44: 57-67.
[25]	Canova C, Ludvigsson J, Baldo V, et al. Risk of bacterial pneumonia and pneumococcal infection in youths with celiac disease—a population-based study. Dig Liver Dis 2019; 51: 1101-1105.
[26]	Zingone F, D’Odorico A, Lorenzon G, et al. Risk of COVID-19 in celiac disease patients. Autoimmunity Rev 2020; 19: 102639.
[27]	Gokden Y, Hot S, Adas M, et al. Celiac disease and COVID-19 pandemic: should we worry? Acta Gastroenterol Belg 2020; 83: 517-525.
[28]	Monzani A, Lionetti E, Felici E, et al. Adherence to the gluten-free diet during the lockdown for COVID-19 pandemic: a web-based survey of Italian subjects with celiac disease. Nutrients 2020; 12: 3467.
[29]	Siniscalchi M, Singole G, Savarino EV, et al. COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine. Dig Liver Dis 2020; 52: 1071-1075.
[30]	Catassi GN, Vallorani M, Cerloni F, et al. A negative fallout of COVID-19 lockdown in Italy: life-threatening delay in the diagnosis of celiac disease. Dig Liver Dis 2020; 52: 1092-1093.
[31]	Schiepatti A, Alimenti E, Naimaris S, et al. Prevalence, incidence and clinical features of SARS-CoV-2 infection in adult celiac patients. Eur J Gastroenterol Hepatol 2021; In press.
[32]	Elli L, Scaramella L, Lombardo V, et al. Refractory celiac disease and COVID-19 outbreak: findings from a high incidence scenario in Northern Italy. Clin Res Hepatol Gastroenterol 2020; 44: e115-e120.
[33]	Freeman HJ. Biopsy-defined adult celiac disease and selective immunoglobulin A deficiency. Int J Celiac Disease 2017; 5: 10-13.
[34]	Naito Y, Takagi T, Yamamoto T, et al. Association between selective IgA deficiency and COVID-19. J Clin Biochem Nutr 2020; 67: 122-125.